Activate seven additional clinical trial sites for the EPISOD1 study
Not delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 15 Oct 2024
- Due
- 31 Mar 2025
- Checked
- 7 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“There are currently four active sites in the U.S. with plans to activate seven additional sites by the first quarter of 2025.”
What we found
Evidence strength A What the grades mean
No evidence that seven additional EPISOD1 sites were activated by Q1 2025 deadline. Trial later paused enrollment in September 2025 due to safety concerns.
-
A uniQure 2025 10-K Filing
“In September 2025, we voluntarily paused enrollment in EPISOD1 upon the recommendation of the IDMC following a review of available preliminary data related to the safety and efficacy of AMT-162 in the context of a dose limiting toxicity, which resulted in an SAE determined to be related to AMT-162, ” ✓ confirmed on the page
-
A uniQure October 15, 2024 Press Release
“There are currently four active sites in the U.S. with plans to activate seven additional sites by the first quarter of 2025.” ✓ confirmed on the page
-
D uniQure N.V. (QURE) Q1 2025 Earnings Call Transcript
“Following the implementation of FDA-cleared protocol amendments to broaden eligibility, the trial now has 12 active clinical sites with more expected to be activated throughout the year.”
Checked 7 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Activate
- Deliverable
- seven additional clinical trial sites
- Where
- United States
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesGemini (Google) re-read the evidence blind and read it as “Met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and reads it as “no_evidence”.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-QURE-001888 · Corrections policy